VMD55 Programme
VMD55 is Aedion's lead asset — a dengue antiviral programme held under a globally structured exclusive licence, advancing through a defined preclinical and clinical pathway.
Lead Asset
VMD55 is Aedion's lead asset, grounded in the pioneering scientific work of Professor Max Reynolds and held under a global exclusive licence and supply framework. Aedion is the single authoritative global holder of the programme — responsible for its development, protection, standardisation, and clinical advancement.
VMD55 is not a theoretical programme. The predecessor compound to VMD55 completed a Phase III clinical trial in Indonesia — demonstrating significant antiviral activity against dengue virus, a well-characterised safety profile, and the capacity to maintain endothelial homeostasis and prevent plasma leakage. VMD55 advances that proven scientific foundation under a globally structured development framework.
| Asset | VMD55 |
| Primary Indication | Dengue |
| Future Expansion | Adjacent high-burden mosquito-borne viral diseases |
| Rights Structure | Global exclusive licence and supply framework — single global holder |
| Scientific Origin | Pioneering research programme of Professor Max Reynolds |
| Development Stage | Pre-clinical to clinical pathway; priority markets identified |
| IP Strategy | Active protection and strategic expansion of surrounding intellectual property |
| Quality Standard | GMP-aligned international quality development pathway |
| Regulatory Plan | Regulatory strategy mapped for priority dengue-endemic markets |
Clinical Evidence
The predecessor compound to VMD55 has already completed a Phase III clinical trial in Indonesia — providing a substantive clinical evidence base that meaningfully de-risks the VMD55 programme relative to a conventional early-stage asset. This is not a compound starting from first principles.
The trial concluded that the predecessor compound demonstrated antiviral activity against dengue virus, was well tolerated with no hepatotoxic or nephrotoxic effects, and was suitable for adoption as a standard treatment for dengue patients. VMD55 is being advanced on the foundation of that established evidence.
Phase III clinical trial conducted in Indonesia. Results pertain to the predecessor compound to VMD55 and do not constitute regulatory approval of VMD55. Aedion Therapeutics is advancing VMD55 through an independent development and regulatory pathway.
Development Pathway
Aedion is advancing VMD55 through a rigorous, systematically planned development pathway appropriate for priority dengue-endemic markets and designed to maintain internationally credible regulatory standards throughout.
Development Mandate
Aedion was not created to start from zero. Its mandate is specific: to secure, protect, standardise, and advance an existing body of scientific work through the commercial, legal, and clinical infrastructure needed to make it a globally credible therapeutic asset.
Rights & IP Structure
Platform Potential
While Aedion's immediate focus is the disciplined development of VMD55 in dengue, the company is structured from the outset to become a broader platform in mosquito-borne and viral disease therapeutics.
The expertise, infrastructure, regulatory relationships, and scientific credibility built through the VMD55 programme create a natural foundation for expansion into adjacent indications and assets over time.
Detailed due diligence materials — including regulatory strategy, IP documentation, and clinical planning — are available in the Aedion Data Room.